GlassScriptPhysician profile
Zalman M Kahn
NPI 1649200205
$1,208.99
in general payments reported to CMS, 2019-2025
15 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $49.30 · 2021: $195 · 2022: $45.35 · 2023: $115 · 2024: $257 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $237.01 | 2019-2022 | |
| Medtronic, INC. | $225.86 | 2023-2024 | Azure Xt Dr Mri Surescan, Corevalve Evolut R |
| Novo Nordisk INC | $170.12 | 2024-2025 | Wegovy |
| Medtronic Vascular, INC. | $128.28 | 2019 | |
| Amgen INC. | $122.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $105.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.25 | 2021-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $32.40 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.43 | 2022-2025 | Lifevest |
| Abbott Laboratories | $18.87 | 2019 | |
| Scpharmaceuticals INC. | $18.45 | 2023 | |
| Pfizer INC. | $15.74 | 2019 | |
| Tactile Systems Technology INC | $15.56 | 2025 | Flexitouch Plus, Nimbl |
| Lexicon Pharmaceuticals, INC. | $15.33 | 2024 | |
| Kestra Medical Technology Services, INC. | $13.68 | 2023 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zalman Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.